Group 1 - Freshpet, Inc. will report its second quarter results for the period ended June 30, 2025, on August 4, 2025, before market open [1] - A conference call with the executive management team is scheduled for August 4, 2025, at 8:00 a.m. ET to discuss the results [2] - The conference call will be available for live broadcast on the company's website and will be archived for later access [3] Group 2 - Freshpet's mission is to provide fresh food for pets, using locally sourced ingredients and cooking in small batches to maintain quality [4] - The company's products are available in various retail formats across the U.S., Canada, and Europe, as well as online in the U.S. [5]

CARLSBAD, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2025, before the market opens on Tuesday, July 29, 2025. John Aballi, Exagen’s President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company’s results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-38 ...

Core Points - Orrstown Financial Services, Inc. will report its second quarter 2025 earnings on July 22, 2025, after market close [1] - A conference call and webcast to discuss the quarterly results will take place on July 23, 2025, at 9:00 am ET [1] Earnings Release Details - Earnings Release Date: July 22, 2025, After Market Close [1] - Conference Call and Webcast Date: July 23, 2025, 9:00 am ET [1] - Webcast Link: https://events.q4inc.com/attendee/935555390 [2] - Telephone Participation: - USA / International Toll: +1 (646) 307-1963 - USA - Toll-Free: (800) 715-9871 - Canada - Toronto: (647) 932-3411 - Canada - Toll-Free: (800) 715-9871 - Conference ID: 5555102 [2] Recorded Playback Information - Audio recording available until July 30, 2025 - US & Canada Toll-Free: (800) 770-2030 - US Toll: (609) 800-9909 - Canada Toll: (647) 362-9199 - Playback ID: 5555102 - Recording also accessible in the Investor Relations section of the Company's website [3] Company Overview - Orrstown Financial Services, Inc. has $5.4 billion in assets and offers a variety of consumer and business financial services across multiple counties in Pennsylvania and Maryland [4] - The lending area includes counties in Pennsylvania, Maryland, Delaware, Virginia, West Virginia, and the District of Columbia within a 75-mile radius of the Company's offices [4] - The Company's common stock is traded on NASDAQ under the symbol "ORRF" [4]

Core Insights - PubMatic, Inc. will release its financial results for Q2 2025 on August 11, 2025, after market close [1] - A webcast to discuss the financial results will be held at 1:30 p.m. Pacific Time [1][3] Company Overview - PubMatic is an independent technology company focused on enhancing customer value in the digital advertising supply chain [2] - The company provides a sell-side platform that empowers digital content creators to manage their inventory and increase monetization [2] - Since its inception in 2006, PubMatic has utilized an infrastructure-driven approach for real-time data processing and utilization [2]

Core Insights - Nuwellis, Inc. has been granted U.S. Patent No. 12,357,734 for innovations in blood filtering and fluid management, enhancing its intellectual property portfolio [1][3] - The patent addresses inaccuracies in fluid balance calculations in continuous renal replacement therapy (CRRT) systems by incorporating fluid density, which can lead to clinically relevant errors if uncorrected [2] - The CEO of Nuwellis emphasized the importance of expanding the intellectual property portfolio as a strategy for long-term value creation through innovation [3] Company Overview - Nuwellis, Inc. is a medical technology company focused on fluid management solutions, particularly the Aquadex SmartFlow system for ultrafiltration therapy [5] - The Aquadex SmartFlow system is designed for patients suffering from fluid overload, providing a clinically proven method for excess fluid removal [6] - The company is headquartered in Minneapolis and has a wholly owned subsidiary in Ireland [5] Patent Details - The newly issued patent covers methods that allow CRRT systems to account for fluid density variations, improving volumetric flow tracking accuracy [2] - This innovation is crucial for enhancing the performance of extracorporeal fluid management systems [3]

PALO ALTO, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Upwork Inc. (Nasdaq: UPWK), the world’s largest work marketplace that connects businesses with independent talent from across the globe, today announced that it will report its financial results for the second quarter of 2025 on Wednesday, August 6, 2025 after market close. The company will host a Q&A conference call to discuss these results at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) on the same day. A live webcast of the call will be available on ...

Receives First Commercial Order for AlMax™ MaterialsNORTON, Mass., July 15, 2025 (GLOBE NEWSWIRE) -- CPS Technologies announced today the award of its fourth Small Business Innovation Research (SBIR) contract of the year, continuing its partnership with the U.S. Navy to support next-generation defense solutions. This Phase I SBIR contract focuses on reducing the weight of the Amphibious Combat Vehicle (ACV), a vital transport platform for U.S. Marine Corps operations on both land and sea. Under the six-mont ...

Core Insights - Biocon Biologics Ltd has received FDA approval for Kirsty™ (Insulin Aspart-xjhz), marking it as the first and only interchangeable biosimilar to NovoLog® in the U.S. [1][2][3] - Kirsty™ is a rapid-acting human insulin analog aimed at improving glycemic control in both adults and pediatric patients with diabetes mellitus [1][3]. - The approval of Kirsty™ enhances Biocon Biologics' biosimilar insulin portfolio, which includes Semglee® (Insulin Glargine-yfgn Injection) [2][3]. Company Overview - Biocon Biologics is recognized as a global leader in biosimilars and insulin production, providing over 9.2 billion doses of insulin globally [4]. - The company has achieved several industry milestones, including the first approval of biosimilar Trastuzumab in the U.S. and has a comprehensive portfolio of 20 biosimilar assets across various therapy areas [5][11]. - Biocon Biologics serves over 5.8 million patients annually across more than 120 countries, focusing on affordable access to high-quality biosimilars [10][11]. Market Context - There are approximately 38.4 million people with diabetes in the U.S., representing about 11.6% of the total population, with nearly a quarter undiagnosed [3]. - The U.S. sales of Insulin Aspart were approximately $1.9 billion in 2024, indicating a significant market opportunity for Kirsty™ [3].

Core Insights - Sintana Energy Inc. has received a 12-month extension for Petroleum Exploration License 79 (PEL 79) in Namibia, now valid until July 2026, allowing further exploration activities [2][6] - The joint venture partners include the National Petroleum Corporation of Namibia (NAMCOR) and Giraffe Energy Investments, with Sintana holding a 49% interest in Giraffe [2][3] - PEL 79 is strategically located near other licenses with significant oil discoveries, enhancing its potential value [3][5] Exploration and Development - PEL 79 is supported by extensive seismic data, including over 4,760 km of 2D seismic and 1,137 km² of 3D seismic, along with a well that has shown gas indications [3] - The area is experiencing increased drilling activity, with nearby operators like Rhino Resources having made significant oil discoveries, including a flow test of over 11,000 barrels per day from the Capricornus-1X well [5][6] - Sintana anticipates material progress across its Namibian offshore portfolio in the coming quarters, leveraging the extension of PEL 79 [6]

CULVER CITY, Calif., July 15, 2025 (GLOBE NEWSWIRE) -- Snail, Inc. (Nasdaq: SNAL) (“Snail Games” or the “Company”), a leading global independent developer and publisher of interactive digital entertainment, announced its intention to explore pursuing a strategic digital asset initiative that includes the evaluation and feasibility for introduction of its own proprietary stablecoin. This initiative would be subject to a range of factors, including but not limited to, regulatory approvals, market conditions, ...